SEHK:1686
SEHK:1686IT

SUNeVision (SEHK:1686) Valuation Check as New Board Appointments Signal Potential Strategic Shift

SUNeVision Holdings (SEHK:1686) has just refreshed its leadership bench by adding technology executive Helen Lo as Executive Director and finance veteran Kenny Lam as Independent Non Executive Director, alongside a new Company Secretary, Noel Lok. See our latest analysis for SUNeVision Holdings. The leadership refresh lands at a tricky moment for the stock, with a 1 month share price return of negative 13.37 percent and a 90 day share price return of negative 25.30 percent, even though the...
SEHK:1093
SEHK:1093Pharmaceuticals

Will New Depression and Metabolic Trial Approvals Change CSPC Pharmaceutical Group's (SEHK:1093) Narrative?

In late 2025, CSPC Pharmaceutical Group announced multiple regulatory approvals in the U.S. and China to begin clinical trials for innovative therapies targeting major depressive disorder, obesity and overweight with comorbidities, and complement-mediated diseases such as IgA nephropathy. By advancing a 5-HT2A agonist without hallucination risk, a dual-biased GLP-1/GIP agonist, and an ultra-long-acting C5 siRNA, CSPC is pivoting its pipeline toward high-demand areas where existing treatment...